AbbVie Ups Its IBD Game With Latest Crohn’s Data For Rinvoq
Last Of Three Phase III Readouts Also Positive
The leader in inflammatory bowel disease via Humira, AbbVie awaits a US FDA decision in June for Skyrizi in Crohn’s disease and plans to add a Crohn’s indication to Rinvoq’s ulcerative colitis approval.
You may also be interested in...
The arrival on the US eczema market of a couple of oral JAK inhibitors with stellar data on itching could provide a challenge to Sanofi and Regeneron's blockbuster Dupixent. However, Pfizer and AbbVie will have to overcome dermatologists' fears about the class-effect safety warnings their drugs come with.
Pfizer, AbbVie and Lilly will face new safety restrictions on Xeljanz, Rinvoq and Olumiant. Indication expansion remains uncertain, while first-line use appears out of the question.
Continuing its longstanding effort to assure investors about growth past Humira’s US patent expiry in 2023, the pharma outlined label-expansion and market share plans for its two newer immunology drugs.